Objective To evaluate if induction of labour at 41 weeks improves perinatal and maternal outcomes in women with a low risk pregnancy compared with expectant management and induction of labour at 42 weeks. Design Multicentre, open label, randomised controlled superiority trial. Setting 14 hospitals in Sweden, 2016-18. Participants 2760 women with a low risk uncomplicated singleton pregnancy randomised (1:1) by the Swedish Pregnancy Register. 1381 women were assigned to the induction group and 1379 were assigned to the expectant management group. Interventions Induction of labour at 41 weeks and expectant management and induction of labour at 42 weeks. Main outcome measures The primary outcome was a composite perinatal outcome including one or more of stillbirth, neonatal mortality, Apgar score less than 7 at five minutes, pH less than 7.00 or metabolic acidosis (pH 12 mmol/L) in the umbilical artery, hypoxic ischaemic encephalopathy, intracranial haemorrhage, convulsions, meconium aspiration syndrome, mechanical ventilation within 72 hours, or obstetric brachial plexus injury. Primary analysis was by intention to treat. Results The study was stopped early owing to a significantly higher rate of perinatal mortality in the expectant management group. The composite primary perinatal outcome did not differ between the groups: 2.4% (33/1381) in the induction group and 2.2% (31/1379) in the expectant management group (relative risk 1.06, 95% confidence interval 0.65 to 1.73; P=0.90). No perinatal deaths occurred in the induction group but six (five stillbirths and one early neonatal death) occurred in the expectant management group (P=0.03). The proportion of caesarean delivery, instrumental vaginal delivery, or any major maternal morbidity did not differ between the groups. Conclusions This study comparing induction of labour at 41 weeks with expectant management and induction at 42 weeks does not show any significant difference in the primary composite adverse perinatal outcome. However, a reduction of the secondary outcome perinatal mortality is observed without increasing adverse maternal outcomes. Although these results should be interpreted cautiously, induction of labour ought to be offered to women no later than at 41 weeks and could be one (of few) interventions that reduces the rate of stillbirths. Trial registration Current Controlled Trials ISRCTN26113652.
11 March 2020 in BJOG: An International Journal of Obstetrics & Gynaecology
Objective: To investigate the risk of gestational diabetes mellitus (GDM) associated with systemic lupus erythematosus (SLE) by comparing pregnancies in women with SLE to general population controls.Methods: We identified singleton pregnancies among women with SLE and general population controls in the Swedish Medical Birth Register (MBR; 2006–2016), sampled from the population-based Swedish Lupus Linkage (SLINK) cohort (1987–2012). SLE was defined by ≥ 2 International Classification of Diseases (ICD)-coded visits in the National Patient Register (NPR) and MBR, with ≥ 1 visit before pregnancy. GDM was defined by ≥ 1 ICD-coded visit in the NPR or MBR. Glucocorticoid (GC) and hydroxychloroquine (HCQ) dispensations within 6 months before and during pregnancy were identified in the Prescribed Drug Register. Risk ratios (RRs) and 95% CIs of GDM associated with SLE were estimated using modified Poisson regression models, stratified by parity and adjusted for maternal age at delivery, year of birth, and obesity.Results: We identified 695 SLE pregnancies including 18 (2.6%) with GDM and 4644 non-SLE pregnancies including 65 (1.4%) with GDM. Adjusted RRs of GDM associated with SLE were 1.11 (95% CI 0.38–3.27) for first deliveries and 2.03 (95% CI 1.21–3.40) for all deliveries. Among SLE pregnancies, GDM occurred in 7/306 (2.3%) with ≥ 1 GC before and/or during pregnancy, 11/389 (2.8%) without GC, 7/287 (2.4%) with ≥ 1 HCQ before and/or during pregnancy, and in 11/408 (2.7%) without HCQ.Conclusion: When looking at all deliveries, SLE was associated with a 2-fold higher risk of GDM. GDM occurrence did not differ by GC or HCQ.
21 July 2021 in Acta Obstetricia et Gynecologica Scandinavica
Introduction: One in four women giving birth in Sweden is foreign‐born. Immigrant status has been suggested as a risk factor for adverse perinatal outcomes. It is not known if infants to foreign‐born women have an increased risk of severe birth asphyxia, or which factors might mediate such association.Material and methods: A population‐based cohort study of 726 730 live births at 36 weeks of gestation or more in Sweden in 2009–2015. The exposure was maternal country of birth, grouped according to the World Bank country classification: low‐, lower‐middle, upper‐middle, and high‐income economies. The main outcome was neonatal hypoxic ischemic encephalopathy (HIE). The outcome was estimated by severity and classified as non‐hypothermia‐treated HIE, representing mainly mild cases, and hypothermia‐treated HIE, representing moderate to severe cases. A secondary outcome was low Apgar score at 5 minutes, defined as <7 or <4. Odds ratios with 95% CI were calculated, using Swedish‐born women as the reference. Structural equation modeling was used to investigate potential mediation of known antepartum risk factors.Results: A total of 854 infants were diagnosed with HIE and 398 received therapeutic hypothermia. Offspring of mothers born in low‐income countries had the highest incidences of HIE and low Apgar score, with an incidence of therapeutic hypothermia of 1.1 per 1000. Compared with offspring of Swedish‐born mothers, these neonates had an almost two‐fold increased risk of HIE, with or without hypothermia treatment (odds ratio 1.7; 95% CI 1.2–2.7 and odds ratio 1.7; 95% CI 1.2–2.6, respectively), and a 2‐ to 3‐fold increased risk of low Apgar score. The structural equation model analysis indicated an exclusive direct effect of country of birth on HIE. Factors reflecting socio‐economic status mediated a small proportion of the risk of Apgar score <7 at 5 minutes.Conclusions: Offspring of women born in low‐income countries had associations with severe birth asphyxia, with increased risk of both HIE and low Apgar score at 5 minutes. The associations seemed only to be marginally mediated by other antepartum factors. The associations are complex and further studies are needed to find explanatory and potentially preventable factors.
6 May 2021 in Paediatric and Perinatal Epidemiology
Background: Early‐onset preeclampsia, traditionally defined as presenting before 34 gestational weeks, is associated with even higher risks of perinatal death, placental abruption, and stroke, than late‐onset preeclampsia.Objective: We estimated the degree of misclassification in a high‐risk population of lupus pregnancies and a general population comparator when gestational age at delivery defined preeclampsia phenotype compared to first preeclampsia diagnosis.Methods: Patients with lupus and general population comparators from Sweden with ≥1 singleton pregnancy in the Medical Birth Register with a documented ICD code for preeclampsia were included (2002‐2016). We used gestational age at delivery (<34 versus ≥34 weeks) to phenotype preeclampsia early‐ versus late‐onset and then reclassified based on first preeclampsia diagnosis date in the Patient Register. We cross‐tabulated the two definitions and calculated sensitivity using the visit‐based definition as the reference standard for general population and lupus pregnancies, overall and among nulliparous women.Results: 331 pregnancies were diagnosed with preeclampsia, of which 322 were in both registers. Of those, 58 were early‐onset based on gestational age at delivery (n = 29 in lupus pregnancies). Overall, 9% of early‐onset preeclampsia in lupus (sensitivity 91%, 95% confidence interval [CI] 75, 98) was misclassified as late‐onset compared to 19% in the general population (sensitivity 81%, 95% CI 64, 92). We noted similar misclassification (4% vs 22%) among nulliparous women.Conclusions: In the general population, early‐onset preeclampsia was more likely misclassified as late‐onset than in the high‐risk lupus population. Relying on gestational age at delivery to phenotype preeclampsia, this way underestimates the occurrence of early‐onset preeclampsia. This also suggests that the burden of early‐onset preeclampsia as a public health concern may be under‐reported, although this may be more applicable to milder preeclampsia where expectant management is employed. Research of biological and maternal predictors of early‐onset preeclampsia may be dealing with differentially misclassified outcomes or samples.
20 November 2018 in Acta Obstetricia et Gynecologica Scandinavica